Interview with Eli Gilboa, PhD
Eli Gilboa Ph.D. Dodson Professor of Microbiology & Immunology University of Miami Miller School of Medicine How did you become interested in the field of oligonucleotides? A main interest and focus of my lab is cancer immunotherapy. The overall approach has been
Interview with Maureen McKeague, PhD
Maureen McKeague, PhD, Postdoctoral Scholar, Bioengineering Department, Stanford University How did you become interested in the field? I’ve been fascinated with nucleic acids ever since high school biology. In my undergraduate degree, I enjoyed genetics
Congratulations to the Winner of the 2015 OTS Lifetime Achievement Award!
Fritz Eckstein, PhD Max Planck Institute for Experimental Medicine Dr. Eckstein received a Ph.D. in chemistry in 1960 at the University of Bonn in Germany. This was followed by a postdoctoral time at the University of Toronto for 2 years with Prof. H. Baer ...
Interview with Bart Klein
ProQR Therapeutics Property, Head of Intellectual Property How did you become interested in the field? I am a Dutch and European patent attorney with a Masters in Chemical Biology/Molecular Biology from Utrecht University, The Netherlands (Msc. 1988).
2015 Gewirtz Memorial Scholarship Winner: Jana McCaskill, PhD
Jana McCaskill, PhD University of Edinburgh Biography: Jana received her PhD in 2014, working with Nigel McMillan at the University of Queensland Diamantina Institute (Australia). Her doctoral work focused on the development and systemic liposomal delivery of respiratory syncytial virus and Hendra virus targeted siRNAs. ...
2015 OTS Young Investigator Award Winner Frank Rigo, PhD
Frank Rigo, PhD Ionis Pharmaceuticals, Inc. Biography: In 2002, Frank completed his undergraduate studies in molecular biology and biochemistry at Marquette University. From 2002-2008, Frank earned his Ph.D. at UCLA in the Biochemistry Department under Harold Martinson. There, he dissected the mechanistic basis for how ...
Interview with Gerald Zon, PhD, FRSC
How did you become interested in the field? I was working in 1981 as an organic chemist at NIH in the former FDA Bureau of Biologics (now Center for Drug Evaluation & Research), and was asked to help clone the gene for human C-reactive protein by making the required hybridization probe—a mixed-sequence 11-mer oligodeoxynucleotide,
